Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
JN.1.30.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
KP.1.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MN.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.63NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
LE.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LH.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
HW.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.55.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.18.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDK.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LS.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1 (Omicron)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.4 (Omicron)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.5.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
LP.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LF.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LQ.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LY.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MD.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LZ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MB.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.2.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.50NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
unclassifiableNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KS.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HH.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCENSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HN.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GU.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GQ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.5.1.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.2.7.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.9.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.22NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JV.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.36NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used